NCT02792478

Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study

Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type Colorectal Cancer in First-line Treatment: a Prospective, Observational Multi-centre Study in Spain. PERSEIDA Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 238 (actual)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Analysis of freely circulating DNA in liquid biopsies using the BEAMing method

Detailed description

Analysis of freely circulating DNA in liquid biopsies using the BEAMing method is proposed as a technique that may be useful for analysing the RAS mutation status in different types of cancer. However, first it is necessary to evaluate the concordance between the results obtained in tumour samples and liquid biopsies. Primary objective • To evaluate the RAS mutation status at baseline in liquid biopsies in subjects with RAS wild-type metastatic colorectal cancer. Secondary objectives * To evaluate the appearance of new RAS mutations using liquid biopsies at the moment of disease progression. * To evaluate the appearance of new RAS mutations using liquid biopsies prior to radiological documentation of disease progression.

Conditions

• RAS Wild Type mCRC

Timeline

• Start date: 2016-05-06
• Primary completion: 2021-05-31
• Completion: 2021-05-31
• First posted: 2016-06-07
• Last updated: 2024-05-13

Locations

24 sites across 1 country: Spain